Long-Term Blood Pressure Reductions Following Catheter-Based Renal Denervation: A Systematic Review and Meta-Analysis
- 1 June 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Hypertension
- Vol. 81 (6) , e63-e70
Abstract
BACKGROUND: Renal denervation is a recognized adjunct therapy for hypertension with clinically significant blood pressure (BP)-lowering effects. Long-term follow-up data are critical to ascertain durability of the effect and safety. Aside from the 36-month follow-up data available from randomized control trials, recent cohort analyses extended follow-up out to 10 years. We sought to analyze study-level data and quantify the ambulatory BP reduction of renal denervation across contemporary randomized sham-controlled trials and available long-term follow-up data up to 10 years from observational studies. METHODS: A systematic review was performed with data from 4 observational studies with follow-up out to 10 years and 2 randomized controlled trials meeting search and inclusion criteria with follow-up data out to 36 months. Study-level data were extracted and compared statistically. RESULTS: In 2 contemporary randomized controlled trials with 36-month follow-up, an average sham-adjusted ambulatory systolic BP reduction of −12.7±4.5 mm Hg from baseline was observed ( P =0.05). Likewise, a −14.8±3.4 mm Hg ambulatory systolic BP reduction was found across observational studies with a mean long-term follow-up of 7.7±2.8 years (range, 3.5–9.4 years; P =0.0051). The observed reduction in estimated glomerular filtration rate across the long-term follow-up was in line with the predicted age-related decline. Antihypertensive drug burden was similar at baseline and follow-up. CONCLUSIONS: Renal denervation is associated with a significant and clinically meaningful reduction in ambulatory systolic BP in both contemporary randomized sham-controlled trials up to 36 months and observational cohort studies up to 10 years without adverse consequences on renal function.Keywords
This publication has 32 references indexed in Scilit:
- 10-Year Outcomes of Catheter-Based Renal Denervation in Patients With Resistant HypertensionJACC, 2023
- Cardiovascular Risk Reduction After Renal Denervation According to Time in Therapeutic Systolic Blood Pressure RangeJACC, 2022
- Longer-Term All-Cause and Cardiovascular Mortality With Intensive Blood Pressure ControlJAMA Cardiology, 2022
- Long-term follow-up of patients undergoing renal sympathetic denervationClinical Research in Cardiology, 2022
- Renal Denervation for HypertensionJACC: Cardiovascular Interventions, 2021
- Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trialThe Lancet, 2020
- Effect of renal denervation on kidney function in patients with chronic kidney diseaseInternational Journal of Cardiology, 2017
- Cardiovascular and Renal Complications in Patients with Resistant HypertensionCurrent Hypertension Reports, 2014
- Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million peopleThe Lancet, 2014
- Drug Intolerance Due to Nonspecific Adverse Effects Related to Psychiatric Morbidity in Hypertensive PatientsArchives of internal medicine (1960), 2003